{
    "clinical_study": {
        "@rank": "66961", 
        "arm_group": [
            {
                "arm_group_label": "Treatment A", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Treatment B", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Treatment C", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The study is designed to test whether or not the rate and extent of absorption of oxycodone\n      from a proprietary controlled-release formulation is significantly affected by\n      co-administration of alcohol compared with controlled conditions (when the formulation is\n      administered with water).  The primary pharmacokinetic parameters are the peak concentration\n      of oxycodone (Cmax) and the overall exposure level of oxycodone as represented by the area\n      under the plasma concentration-time curve (AUC)."
        }, 
        "brief_title": "Study to Determine the Effects of Co-Administration of Alcohol on the Absorption of Oxycodone From a Proprietary Controlled-Release Formulation", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  healthy volunteers\n\n          -  history of moderate alcohol consumption\n\n          -  total body weight exceeding 64 kg\n\n        Exclusion Criteria:\n\n          -  history of clinically significant disease\n\n          -  history of sleep apnea\n\n          -  any condition affecting drug absorption\n\n          -  pregnant or nursing female subjects\n\n          -  history of allergy or hypersensitivity to either oxycodone or naltrexone"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "19", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01677039", 
            "org_study_id": "B4531004"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment A", 
                "description": "single dose of 20 mg of test formulation with 240 mL of water", 
                "intervention_name": "Test formulation administered with water", 
                "intervention_type": "Drug", 
                "other_name": "ALO-02 20 mg"
            }, 
            {
                "arm_group_label": "Treatment B", 
                "description": "single dose of 20 mg of test formulation with 240 mL of 20% ethanol in water", 
                "intervention_name": "Test formulation administered with 20% ethanol", 
                "intervention_type": "Drug", 
                "other_name": "ALO-02 20 mg"
            }, 
            {
                "arm_group_label": "Treatment C", 
                "description": "single dose of 20 mg of test formulation with 240 mL of  40% ethanol", 
                "intervention_name": "Test formulation administered with 40% ethanol", 
                "intervention_type": "Drug", 
                "other_name": "ALO-02 20 mg"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ethanol", 
                "Oxycodone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Bioavailability", 
            "oxycodone", 
            "ethanol interaction", 
            "healthy volunteers"
        ], 
        "lastchanged_date": "December 10, 2012", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B4531004&StudyName=Study%20to%20Determine%20the%20Effects%20of%20Co-Administration%20of%20Alcohol%20on%20the%20Absorption%20of%20Oxycodone%20from%20a%20Proprietary%20Controlled-Release%20Formul"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06511"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "An Open-label, Single-dose, Randomized, Three-way Crossover Study to Estimate the Effects of Ethanol 20% and 40% on the Bioavailability a Controlled Release Formulation of Oxycodone 20 Mg With Sequestered Naltrexone 2.4 Mg in Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum observed oxycodone concentration in plasma (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "hours after dosing"
            }, 
            {
                "measure": "Area under the oxycodone concentration versus time curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "hours after dosing"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01677039"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time-to-peak concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "hours after dosing"
            }, 
            {
                "measure": "half-life of drug", 
                "safety_issue": "No", 
                "time_frame": "hours after dosing"
            }, 
            {
                "measure": "Vital signs and adverse events", 
                "safety_issue": "No", 
                "time_frame": "hours after dosing"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}